Origins of lung adenocarcinoma from lung cells like AT1 and AT2
Official title: Elucidating the Cellular Origins of lung adenocarcinoma
Funded at Beckman Research Institute/city of Hope · NIH-11348850 · Data updated 2026-11-12
A cancer research project is exploring where a common form of lung cancer starts in the lung’s air sacs and how it develops.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | July 11, 2023 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $425,575 |
| NIH project number | 5R01CA262258-04 |
| Project ID | NIH-11348850 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with lung adenocarcinoma or a family history who may benefit from improved classification or targeted therapies in the future.
✕Less likely to help
People without LUAD or without a potential link to the tumor origins studied may not directly benefit.
What this research studies
This project investigates how lung adenocarcinoma may begin in different lung cell types, including AT1 and AT2 cells, and how these origins relate to cancer subtypes and gene changes. Researchers use a mouse model with a KrasG12D driver in AT1 cells to study tumor formation and its unique molecular signatures, especially TGF-β–related pathways. The study aims to connect cellular origin with tumor behavior, progression, and histology to better understand future treatment strategies. The findings could help identify new targets for therapies and improve how we classify LUAD in patients.
Why it matters
Potential benefit: If successful, this work could reveal new targets for treatment and improve how LUAD is diagnosed and classified, potentially guiding personalized care.
How similar studies have gone: Prior mouse-model studies support that LUAD can originate from specific alveolar and airway cells, but translating origins to human disease remains an active area.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Marconett, Crystal Nicole — Beckman Research Institute/city of Hope
- Study coordinator: Marconett, Crystal Nicole
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.